A second small molecule drug, PRI-724, blocks wnt signaling through antagonism of β-catenin/TCF-mediated transcription, resulting in down-regulation of β-catenin/TCF-responsive genes [88], potentially including IDO in tumor-associated macrophages/DC. Here, HNF4A is linked to neoplasm.